65 completed, 8 active not recruiting, 7 terminated, 4 recruiting. 22 Phase 3, 20 Phase 1, 12 Phase 2, 10 Phase 4, 4 Early Phase 1.
Follow Janssen Pharmaceutica N.V., Belgium: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab. Teclistamab, Talquetamab, Daratumumab - Multiple Myeloma (MM) | Phase 2 | Recruiting | European Myeloma Network B.V. | 150 | 2025-12-12 | 2026-04-15 |
| Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer SX-682, Apalutamide - Metastatic Castrate-Resistant Prostate Cancer (mCRPC) | Phase 1 / Phase 2 | Recruiting | Institute of Cancer Research, United Kingdom | 78 | 2025-04-28 | 2026-09-08 |
| BEhavioral and Adherence Model for Improving Quality, Health Outcomes and Cost-Effectiveness of healthcaRe B-COMPASS implementation - Cardiovascular Diseases, Endocrinology | Not applicable | Completed | Technical University of Madrid | 6190 | 2025-03-01 | 2026-10-21 |
| Effects of Combination Medical Therapy Followed by BPA on Right Ventricular-PA Coupling and Hemodynamics in CTEPH Macitentan Tablets, Riociguat, balloon pulmonary angioplasty - CTEPH | Phase 3 | Terminated | Dr Sudarshan Rajagopal | 7 | 2025-01-27 | 2026-09-03 |
| 5G-EMERALD: Amivantamab in Malignant Brain Tumours Amivantamab - Malignant Primary Gliomas, Glioblastoma Multiform (Grade IV Astrocytoma) | Phase 1 | Active not recruiting | Institute of Cancer Research, United Kingdom | 12 | 2024-10-09 | 2026-08-17 |
| A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease JNJ-64042056, Placebo - Alzheimer Disease | Phase 2 | Active not recruiting | Janssen Pharmaceutica N.V., Belgium | 55 | 2024-07-22 | 2026-09-25 |
| Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma Teclistamab, Daratumumab, Lenalidomide - Multiple Myeloma | Phase 2 | Active not recruiting | University Hospital, Lille | 74 | 2023-12-21 | 2026-09-25 |
| Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma Daratumumab, Bortezomib, Lenalidomide - High-Risk de Novo Multiple Myeloma | Phase 2 | Active not recruiting | PETHEMA Foundation | 30 | 2023-09-21 | 2026-05-11 |
| A Study of Milvexian in Healthy Adult Females Milvexian, Midazolam, Ethinylestradiol - Healthy Female | Phase 1 | Completed | Janssen Pharmaceutica N.V., Belgium | 20 | 2023-01-25 | 2025-03-30 |
| A Study in Chronic Hepatitis B e-Antigen Negative Participants After Discontinuation of Nucleos(t)Ide Analog (NA) Treatment Entecavir (ETV), Tenofovir Disoproxil Fumarate (TDF), Tenofovir Alafenamide (TAF) - Hepatitis B, Chronic | Early Phase 1 | Withdrawn | Janssen Pharmaceutica N.V., Belgium | 2022-10-31 | 2025-06-25 | |
| A Study of Ponesimod in Healthy Adult Participants Ponesimod, Carbamazepine - Healthy | Phase 1 | Completed | Janssen Pharmaceutica N.V., Belgium | 28 | 2022-10-18 | 2025-04-27 |
| A Study of JNJ-55308942 in the Treatment of Bipolar Depression JNJ-55308942, Placebo - Bipolar Disorder | Phase 2 | Completed | Janssen Pharmaceutica N.V., Belgium | 116 | 2022-06-03 | 2025-07-11 |
| A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma No intervention - Relapsed/Refractory Multiple Myeloma | Recruiting | Janssen Pharmaceutica N.V., Belgium | 300 | 2021-11-18 | 2026-09-25 | |
| A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice Guselkumab, IL-17i - Arthritis, Psoriatic | Active not recruiting | Janssen Pharmaceutica N.V., Belgium | 1314 | 2021-08-25 | 2026-09-25 | |
| A Study Evaluating Drug Drug Interaction Between Milvexian and Atorvastatin in Healthy Participants Milvexian, Atorvastatin - Healthy | Phase 1 | Completed | Janssen Pharmaceutica N.V., Belgium | 23 | 2021-06-07 | 2025-03-30 |
| Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL) Ibrutinib, Venetoclax, Obinutuzumab - Chronic Lymphoid Leukemia | Phase 3 | Active not recruiting | German CLL Study Group | 897 | 2021-03-01 | 2026-04-30 |
| Adjuvant Apalutamide in Subjects With High-risk Localized or Locally Advanced Prostate Cancer After Radical Prostatectomy Standard of care, Apalutamide 60Mg Tab - Prostatic Neoplasms | Phase 2 | Active not recruiting | Universität Münster | 190 | 2020-12-10 | 2024-06-20 |
| A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer Radiotherapy, LHRHa, Apalutamide - Prostatic Neoplasms | Phase 3 | Active not recruiting | Janssen Pharmaceutica N.V., Belgium | 691 | 2020-11-12 | 2026-09-25 |
| A Study of JNJ-64140284 in Healthy Male Participants JNJ-64140284, Placebo - Healthy | Phase 1 | Terminated | Janssen Pharmaceutica N.V., Belgium | 33 | 2020-09-29 | 2025-04-27 |
| A Study to Evaluate the Effect of Renal Impairment on JNJ-64417184 and Its Two Minor Metabolites JNJ-68294291 and JNJ-65201526 in Adult Participants JNJ-64417184 - Renal Impairment | Phase 1 | Terminated | Janssen Pharmaceutica N.V., Belgium | 6 | 2020-07-03 | 2021-01-15 |
Showing 20 of 87. Sign in to see all of them.
Schizophrenia (14) · Psychotic Disorders (9) · Prostatic Neoplasms (6) · Alzheimer Disease (5) · Multiple Myeloma (5) · Arthritis, Psoriatic (4) · Bipolar Disorder (4) · Arthritis (3) · Attention Deficit Disorder with Hyperactivity (3) · Cognition Disorders (3) · Dementia (3) · Gastroesophageal Reflux (3) · Neoplasms (3) · Attention Deficit and Disruptive Behavior Disorders (2) · Conduct Disorder (2)
Risperidone (11) · apalutamide (4) · Carboplatin (3) · Rabeprazole (3) · daratumumab (3) · quisinostat (3) · Abiraterone Acetate (2) · Darunavir (2) · Ethinyl Estradiol (2) · Fentanyl (2) · Lenalidomide (2) · Nicotine (2) · Paclitaxel (2) · Prednisone (2) · Standard of Care (2)
Belgium (22) · Germany (18) · Spain (16) · United Kingdom (16) · France (15) · United States (15) · Russia (13) · Greece (10) · Netherlands (10) · Switzerland (10) · Austria (9) · Norway (8) · Sweden (8) · Denmark (7) · Italy (7)
Alessandra Larocca (1) · Ashkan Mortezavi, MD, PhD (1) · Barbara A Cornblatt, PhD (1) · Christoph U Correll, MD (1) · Dawn I Velligan, Ph.D. (1) · Fredrik Schjesvold (1) · Gabor I Keitner, M.D. (1) · Giuseppe Fico, Professor (1)
PMID 10496251, PMID 12153826, PMID 12218423, PMID 12562742, PMID 15233698, PMID 15289699, PMID 15480678, PMID 15572280, PMID 15701214, PMID 15958159, PMID 17988947, PMID 18206857, PMID 19042161, PMID 20384968, PMID 22339430, PMID 22766391, PMID 22780962, PMID 23441978, PMID 28477061, PMID 30423462, PMID 31246234, PMID 31594705, PMID 32500294, PMID 32586393, PMID 32923850, PMID 33794293, PMID 33826036, PMID 34819273, PMID 35210262, PMID 35317973, PMID 35841526, PMID 36585602, PMID 36600178, PMID 36642439, PMID 36791792, PMID 36810788, PMID 37353788, PMID 37587493, PMID 37906417, PMID 38110653, PMID 38402374, PMID 38488975, PMID 38725258, PMID 39164518, PMID 39362933, PMID 39498781, PMID 39547694, PMID 40263079, PMID 41313549, PMID 41326161
2019 (6), 2018 (2), 2023 (2), 2004 (1), 2005 (1), 2017 (1)